
Pharmacally
Gout
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Gout
Clinical TrialsAtom’s Lingdolinurad Delivers Strong Phase 2b Gout ResultsAtom Therapeutics’ lingdolinurad achieved higher serum urate target attainment than febuxostat in a Phase 2b gout study, with 91.9% of patients reaching the primary urate target at Week…Fact-Checked
Clinical TrialsJW Pharmaceutical’s Epaminurad 6 mg Shows Superiority Over Febuxostat in Gout TrialJW Pharmaceutical reported that investigational hURAT1 inhibitor epaminurad 6 mg achieved statistical superiority over febuxostat 40 mg for serum uric acid control in the Phase 3 EPIC trial…Fact-Checked
Health TidingsCrystalys Therapeutics Raises $130 Million to Advance Phase 3 Development of Dotinurad for GoutCrystalys Therapeutics has closed an oversubscribed $130 million Series B financing to support the late-stage clinical development of dotinurad, an investigational once-daily oral URAT1 inhibitor for gout.Fact-Checked
Clinical TrialsSobi’s Pozdeutinurad Delivers Positive Phase 3 Results in GoutSobi has reported positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad (AR882), an investigational oral URAT1 inhibitor, in adults with gout inadequately controlled…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.